Risk-Adapted Frameworks Reshape Pediatric Neuroblastoma Care, New Review Shows
核心洞察
Neuroblastoma (搜索), the most common extracranial solid tumor in children under five, accounts for approximately 15% of pediatric cancer deaths, with five-year survival below 60% for high-risk cases.
A narrative review published in the World Journal of Pediatric Surgery synthesizes current evidence on risk-adapted diagnosis, treatment sequencing, and long-term survivorship care.
The International Neuroblastoma (搜索) Risk Group Staging System (INRGSS) and molecular markers such as MYCN (搜索) amplification guide treatment intensity, ranging from observation alone to multimodal therapy.
Neuroblastoma (搜索) remains one of the most unpredictable childhood cancers, with a clinical spectrum ranging from tumors that spontaneously regress without treatment to aggressive disease that resists intensive therapy. Now, a comprehensive narrative review published on January 6, 2026, in the World Journal of Pediatric Surgery offers pediatric specialists an updated, unified framework for risk-adapted care—spanning diagnosis, risk classification, surgery, chemotherapy, immunotherapy, and long-term survivorship.
The review, authored by specialists from the Department of Pediatric Surgery at the Royal Hospital for Children in Glasgow (搜索) and the Department of Pediatric Surgery at the University of Liverpool, synthesizes current evidence on clinical presentation, imaging, pathology, molecular biology, staging, and treatment of childhood neuroblastoma (搜索). It also examines major surgical controversies, emerging targeted therapies, relapse patterns, and the long-term health needs of survivors.
A Disease of Striking Biological Diversity
Neuroblastoma (搜索) is the most common solid tumor outside the brain in children younger than five years old and accounts for about 15% of pediatric cancer deaths. Its biology is unusually diverse: some tumors in infants disappear spontaneously, while others spread rapidly, surround major blood vessels, recur after treatment, or cause lasting complications. Five-year survival exceeds 90% for low- and intermediate-risk disease but remains below 60% for high-risk cases. Clinicians must therefore balance treatment intensity against surgical risk, organ preservation, toxicity, and future quality of life.
Pretreatment Risk Assessment as the Cornerstone of Care
The review demonstrates how pretreatment risk assessment shapes every step of care. Approximately 70% of patients present with abdominal disease, and diagnosis commonly combines urine catecholamine testing, magnetic resonance imaging (MRI), meta-iodobenzylguanidine (MIBG) scintigraphy, bone marrow assessment, biopsy, and genetic profiling.
The International Neuroblastoma (搜索) Risk Group Staging System (INRGSS) uses imaging findings and the presence or absence of image-defined risk factors (IDRFs) to classify localized, metastatic, and special metastatic disease before treatment. Molecular markers add another critical layer: MYCN (搜索) amplification occurs in roughly one-quarter of tumors and in 40%–50% of high-risk cases, where it signals aggressive behavior.
Tailoring Treatment Across the Risk Spectrum
Treatment strategies range dramatically based on risk classification. For selected infants and low-risk patients, observation or surgery alone may suffice. For high-risk disease, the standard involves chemotherapy, surgery, myeloablative therapy, autologous stem cell rescue, radiotherapy, GD2-targeting monoclonal antibodies (搜索), and retinoic acid.
The authors highlight compelling data supporting conservative management in carefully selected cases: a prospective study reported 10-year event-free survival of 94.7% and overall survival of 97.4% for infants monitored without immediate intervention, supporting observation when strict criteria are met.
Unresolved Questions and Emerging Therapies
The review also identifies unresolved questions in the field. Computed tomography (CT) may better define surgical anatomy than MRI in some high-risk abdominal tumors, while the survival benefit of more extensive resection remains debated. Standardized surgical reporting may help future trials distinguish complete removal from incomplete resection more reliably.
The discussion of GD2-targeting monoclonal antibodies (搜索), chimeric antigen receptor T-cell therapy, mutations in the anaplastic lymphoma kinase (ALK (搜索)) gene, and telomere biology points toward more personalized treatment approaches.
The authors emphasized that neuroblastoma (搜索) cannot be managed with a single formula. "The safest and most effective plan depends on seeing the child's age, tumor biology, anatomical risk, and likely treatment response as one connected picture," they stated. For some infants, that may mean close observation rather than immediate intervention; for high-risk disease, it means coordinated multimodal care, careful surgical judgment, and new therapies that control the tumor without adding avoidable harm.
Beyond Survival: The Long-Term View
The authors stress that survival is not the only endpoint. Fertility, hearing, endocrine health, cognition, emotional well-being, and secondary cancers require lifelong follow-up as more children survive neuroblastoma (搜索). These priorities could shape both clinical protocols and future trial design.
The review holds value for surgeons, oncologists, radiologists, pathologists, and multidisciplinary tumor boards. Its risk-based framework can support more consistent decisions about when to observe, biopsy, operate, or intensify therapy. Wider use of structured surgical reports could improve international trial comparisons, especially where the true extent of resection remains uncertain.